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for the progression from AKI to chronic 
kidney disease. 7 Interestingly,   -catenin 
activation was frequently detected in 
fi brotic kidney tissues, 8 and inhibition of 
  -catenin signaling reduced fi brosis in the 
model of obstructive nephropathy. 9 Does 
  -catenin also have a role in renal fi brosis? 
In cultured renal tubular cells,   -catenin 
overexpression suppressed E-cadherin 
expression and induced fibronectin, a 
profi brotic factor. Remarkably, ICG-001, 
a pharmacologic inhibitor of   -catenin, 
was able to abolish transforming growth 
factor-  1-induced expression of fi brotic 
genes including fi bronectin, collagen I, 
and   -smooth muscle actin.  In vivo , ICG-
001 also effectively attenuated fibrotic 
lesions in obstructive nephropathy. 10 
Pending further experimental evidence, 
we speculate that   -catenin may also con-
tribute to the development of renal fi bro-
sis aft er AKI and initial repair ( Figure 1 ). 
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 Benefits of short daily home 
hemodialysis in the FREEDOM 
Study: is it about person, 
place, time, or treatment ? 
 Khaled  Abdel-Kader 1 and  Mark L.  Unruh 1 
 Many end-stage renal disease patients receive thrice-weekly 
hemodialysis (HD) and report impairments in health-related quality of 
life (HRQOL). Recent studies indicate that short daily HD may improve 
HRQOL. High-quality studies exploring the burdens and costs to 
patients, caregivers, and society are necessary before widespread 
adoption can be advocated. Further research exploring the mechanisms 
by which these benefits are realized is also important, as many patients 
are likely to opt out of short daily HD. 
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 Despite recent trends of increased use of 
home hemodialysis (HD), the overwhelm-
ing majority of maintenance HD patients 
in the United States receive thrice-weekly 
in-center HD. Unfortunately, the mortal-
ity and health-related quality of life 
(HRQOL) of these patients remain poor. 1 
Much research has focused on modifi ca-
tions to the dialysis procedure in hopes of 
improving these outcomes. Th e Hemo-
dialysis Study showed that improvements 
in middle-molecule clearance or  Kt / V , 
while preserving the thrice-weekly sched-
ule, did not substantively improve mortal-
ity or HRQOL. 2,3 In contrast, the recently 
published Frequent Hemodialysis 
Network (FHN) daily trial showed that 
short daily HD improved the co-primary 
outcomes (mortality or left  ventricular 
mass, and mortality or physical-health 
composite score of the RAND 36-item 
health survey) as well as predialysis phos-
phorus and systolic blood pressure. 4 
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 Given the recruitment and logistical 
challenges of the FHN studies, larger ran-
domized controlled trials are unlikely to 
be conducted in the near future. Hence, 
further evidence regarding the potential 
benefi ts, risks, and burdens of short daily 
HD will probably come from large, high-
quality, observational studies. Th e Follow-
ing Rehabilitation, Economics and 
Everyday-Dialysis Outcome Measure-
ments (FREEDOM) Study is an ongoing 
prospective multicenter observational 
study examining the eff ects of at-home 
short daily HD (six times per week) with 
the NxStage System (NxStage Medical) on 
hospitalizations, medical costs, and 
HRQOL. 5 Th e study seeks to enroll 500 
end-stage renal disease (ESRD) patients at 
least 18 years of age who are deemed can-
didates for short daily HD and have Medi-
care as their primary insurer. 
 In this issue of  Kidney International , the 
study investigators report their prespeci-
fied interim analysis on changes in 
HRQOL assessed by the SF-36 health sur-
vey at months 4 and 12 following initia-
tion of at-home short daily HD. 5 Of the 
291 enrolled participants, 154 completed 
assessments at 12 months. After using 
random-eff ects models to address missing 
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data and adjusting for use of psychotropic 
medications, the authors note a four-point 
increase in the mean physical component 
summary (PCS) score at 12 months in 
the total cohort (as well as the as-treated 
cohort). Similar improvements at 12 
months were observed in the SF-36 sub-
scales that contribute to the PCS score. 
Further, there was a signifi cant increase in 
the proportion of participants who 
reported a PCS score of at least 50 (the 
mean score for the US population), from 
less than 10 % at baseline to greater than 
20 % at 12 months. In a subgroup analysis, 
participants with the lowest baseline PCS 
scores (  <  29 – 30) demonstrated the largest 
improvements (six to seven points). In 
addition, modest improvements in mental 
component summary scores were also 
observed. 
 Th e FREEDOM Study possesses several 
strengths, including the multicenter pro-
spective design, the use of a validated 
HRQOL instrument, and the presence of 
repeated HRQOL assessments at 4 and 12 
months. Yet the study ’ s fi ndings must also 
be considered in light of important weak-
nesses ( Figure 1 ). First, as the authors 
acknowledge, is the potential for selection 
bias in a study recruiting participants for 
at-home short daily HD. To what extent is 
the person enrolled in the FREEDOM 
Study similar to those seen in your prac-
tice? It is hard to say, as the investigators 
do not report diff erences between their 
study sample and the larger population of 
patients seen at their centers. Second is 
the lack of a control arm (for example, in 
the recent FHN nocturnal study, both the 
intervention and control arms demon-
strated a two- to three-point signifi cant 
improvement in physical-health compos-
ite scores from baseline). 6 Is it simply that 
FREEDOM enrolled people who would 
engage in a study and report improved 
fi ndings due to a placebo eff ect, or was 
there another temporal change that 
improved HRQOL? Hence, it remains 
unclear whether the observed improve-
ments in the FREEDOM Study represent 
a true eff ect of the intervention or are due 
to placebo or attention eff ects. In addition, 
the approximately 47 % participant attri-
tion and the missing HRQOL data at 12 
months are a reason for pause. Although 
the authors used a random-eff ects pat-
tern-mixture model to handle the missing 
data, patients who were not followed up 
at 12 months may have experienced 
decrements in HRQOL not accurately 
captured by modeling. Nonetheless, 
the FREEDOM Study represents one of 
the largest prospective trials to document 
an improvement in HRQOL with short 
daily HD, and its findings corroborate 
those of the FHN daily trial 4 and multiple 
smaller trials. 7 
 Improving HRQOL in ESRD remains an 
imperative. Patients with ESRD have mark-
edly compromised HRQOL, especially 
related to domains of physical function-
ing. 8 HRQOL has been shown to be an 
important factor when patients think about 
selecting frequent HD. Further, HRQOL is 
independently associated with morbidity 
and mortality in the ESRD population. 9 
Interventions that improve HRQOL in 
ESRD could improve patients ’ sense of 
well-being and may reduce morbidity and 
mortality. A growing body of literature 
appears to indicate that short daily HD 
enhances HRQOL; 4,5,10 however, the 
underlying mechanisms have not been well 
explored. A few processes hypothesized to 
play a role include ( Figure 1 ) the more 
physiologic approach to renal replacement 
therapy, the greater number of  ‘ fi rst hours ’ 
on HD, the improvements in volume sta-
tus, the potentially enhanced social support 
with at-home therapies, and the reduced 
medication burden. Even if short daily HD 
is more eff ective than conventional HD, 
prior experience indicates that many 
patients will continue to opt for fewer treat-
ments. Understanding how short daily HD 
benefi ts HRQOL may allow researchers 
and providers to explore alternative inter-
ventions to extend these improvements to 
ESRD patients unwilling to undergo daily 
HD treatments ( Figure 1 ). 
 Despite its potential advantages, in this 
age of budget defi cits and austerity meas-
ures, further hurdles remain before wide-
spread adoption of daily HD can be 
advocated. Th e work of the FREEDOM 
Study investigators demonstrates that 
those responding to HRQOL surveys aft er 
a year of frequent at-home HD report 
improvements in physical well-being. Th e 
design of this study, however, leaves it 
unclear whether the reported benefi ts are 
due to the type of person selected for the 
study, the place where HD was performed, 
or whether the frequency of dialysis 
improved self-reported physical well-
being. High-quality cost-effectiveness 
analyses are required to better delineate 
the costs and benefi ts of daily HD. Equally 
important are studies examining the 
patient and caregiver burden and long-
term acceptability of short daily HD. 
Th e studies of caregivers are particularly 
important in studying the long-term 
feasibility of a home therapy such as 
home HD. As new technologies improve 
the convenience and lower the expense of 
daily HD, and as the body of data support-
ing its use grows, the time for short daily 
HD may soon be here. 
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 Figure 1  |  Factors potentially contributing to observed improvements in health-related 
quality of life. RRT, renal replacement therapy. 
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 In search of a better 
understanding of IgA 
nephropathy-associated 
hematuria 
 Frank  Eitner 1 , 2 and  J ü rgen  Floege 1 
 Although microscopic or episodic macroscopic hematuria is the key 
clinical manifestation of IgA nephropathy (IgAN), still very little is known 
about its pathogenesis. Cox  et al. studied IgAN patients during episodes 
of macroscopic hematuria and identified an upregulated expression of 
the chemokine receptor CX3CR1 in their circulating leukocytes. On the 
basis of a series of additional experimental approaches, they suggest 
that CX3CR1 and its ligand fractalkine may contribute to the onset of 
macroscopic hematuria in IgAN. 
 Kidney International (2012)  82, 513 – 515.  doi: 10.1038/ki.2012.160 
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 Th e most consistent clinical manifestation 
of IgA nephropathy (IgAN) is the presence 
of hematuria. 1 Clinically, hematuria distin-
guishes two forms of IgAN: up to half of the 
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patients present with episodes of macro-
scopic hematuria, whereas asymptomatic 
microscopic hematuria is the presentation 
in the other half in most reported series. 
Episodes of macrohematuria usually follow 
mucosal infections, commonly in the upper 
respiratory tract or occasionally in the gas-
trointestinal tract, but can also coincide 
with physical exercise. 1,2 In particular, in 
adult IgAN patients, macrohematuria oft en 
precipitates acute kidney injury, and up to 
a quarter of these patients, especially elderly 
patients with prior impairment of the 
glomerular fi ltration rate, do not recover 
completely. 3 
 Does the hematuria pattern separate 
two IgA nephropathy disease entities? 
 During follow-up, episodes of macro-
hematuria are very rare in IgAN patients 
who initially present with asymptomatic 
micro hematuria, yet very frequent in 
patients who initially present with macro-
hematuria. Th is observation has been used 
as an argument that the two hematuria 
patterns separate two distinct disease 
entities. 4 Alternatively, hematuria patterns 
might simply relate to the age at which the 
disease fi rst manifests. Indeed, recurrent 
macrohematuria is the defi ning clinical 
feature in 80 – 90 % of all pediatric IgAN 
patients and is very rarely a presenting 
manifestation aft er the age of 40 years. 1 
 Recurrent macrohematuria has also 
been analyzed for its value as a clinical 
indicator of disease progression. 1 In con-
trast to proteinuria, arterial hypertension, 
and an impaired glomerular fi ltration rate, 
all of which strongly predict a negative 
outcome, a history of recurrent macro-
hematuria appeared to predict a better 
prognosis in IgAN. 1 However, given the 
signifi cantly younger age of patients with 
recurrent macrohematuria, this might 
represent lead-time bias, as such patients 
might simply have had a shorter disease 
duration. Consequently, current IgAN 
treatment suggestions are based on 
glomerular fi ltration rate and degree of 
proteinuria and not on the presence or 
degree of hematuria. 5 
 Studying IgA nephropathy patients 
at the time of overt macroscopic 
hematuria might help in understanding 
disease pathogenesis 
 Remarkably little is known about the 
mole cular mechanisms that cause persist-
ent microscopic or episodic macroscopic 
hema turia in IgAN, and more insight into 
these pathomechanisms might trans late 
into a better understanding of IgAN dis-
ease initiation and progression. 
 In an elegant series of experiments, the 
group of Cox  et al. 6 (this issue) focused on 
macrohematuric IgAN patients. Periph-
eral blood mononuclear cells (PBMCs) 
were isolated from patients during an epi-
sode of macroscopic hematuria and later 
